☆ 4.5 Article

Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Senthil Selvaraj et al.

Summary: The study found positive treatment effects of Dapagliflozin on systolic blood pressure and cardiovascular outcomes in heart failure patients. However, the changes in blood pressure did not completely account for the treatment effects. The study also revealed increased risk in patients with low and high blood pressure, with variations in different endpoints.

JACC-HEART FAILURE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC

Theresa A. McDonagh et al.

Summary: All experts involved in the development of the guidelines have declared their interests, and the declarations have been compiled and published in a supplementary report. The report can be accessed on the ESC website. The supplementary data provide background information and detailed discussion of the data that form the basis for the guidelines.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Initial Decline (Dip) in Estimatec Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF

Carly Adamson et al.

Summary: In heart failure patients with reduced ejection fraction, the early decline in eGFR after dapagliflozin initiation is associated with better clinical outcomes, and large declines in eGFR are rare.

CIRCULATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Paul A. Heidenreich et al.

Summary: The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure provides patient-centric recommendations for the prevention, diagnosis, and management of heart failure, based on contemporary evidence and updated recommendations.

CIRCULATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial

Safia Chatur et al.

Summary: Worsening renal function may impact long-term outcomes in heart failure (HF). This study found that HF hospitalization denotes increased risk for kidney disease progression, and the trajectories of renal function change before and after hospitalization.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced

Faiez Zannad et al.

Summary: This study aims to investigate the impact of early eGFR changes induced by empagliflozin on patients with heart failure. The study found that eGFR changes caused by empagliflozin do not have adverse effects on heart failure, mortality, or kidney safety.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial

Adriaan A. Voors et al.

Summary: Empagliflozin, a SGLT2 inhibitor, caused an initial decline in renal function in patients with acute heart failure, but this effect was not evident after 90 days. Acute renal events were similar in both groups, and the clinical benefit of empagliflozin was consistent regardless of baseline renal function.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction

Jonathan W. Cunningham et al.

Summary: This study investigates the clinical outcomes and response to dapagliflozin in patients with HF, finding that dapagliflozin safely reduces the risk of worsening HF or cardiovascular death in patients recently hospitalized for HF.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon et al.

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Patients Hospitalized for De Novo Versus Worsening Chronic Heart Failure in the United States

Stephen J. Greene et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed

Stephen J. Greene et al.

Summary: This viewpoint argues for increased use of quadruple therapy in patients with heart failure with reduced ejection fraction, emphasizing the importance of this approach in managing the condition effectively.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

Matteo Serenelli et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

The vulnerable phase after hospitalization for heart failure

Stephen J. Greene et al.

NATURE REVIEWS CARDIOLOGY (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Clyde W. Yancy et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)

Add to Collection

Article Statistics & Probability

Semiparametric regression for the mean and rate functions of recurrent events

DY Lin et al.

JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.